Biovie Inc. (NASDAQ:BIVI)
| Market Cap | $8.58M-38.5% |
| Revenue (ttm) | $0 |
| Net Income | -$22.59M-22.3% |
| EPS | -$2.90+67.4% |
| Shares Out | 10.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399,581 |
| Open | $0.87 |
| Previous Close | $0.91 |
| Day's Range | $0.76 - $0.87 |
| 52-Week Range | $0.75 - $3.79 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 5, 2027 |
About BIVI
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Biovie Inc. Stock Analysis — InsiderScore
Biovie Inc. scored higher than 27% of companies evaluated by InsiderBuying, and ranked 59th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Biovie Inc. bought $52.0K of stock across 5 purchases in the last 90 days, the largest of them $31.6K.
The average purchase added about 44% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 5, 2027Earnings report
$BIVI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BIVI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BIVI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BIVI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BIVI Revenue by Segment
| Clinical studies | $2.24M | 67.36% |
| Clinical teams | $1.02M | 30.75% |
| Chemistry, manufacturing and controls | $63.00K | 1.89% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BIVI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BIVI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BIVI
| VXFVanguard Extended Market ETF | $101.40K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BIVI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical data presentations for lead drug bezisterim across Long COVID and Parkinson's indications demonstrate pipeline progress.
Recent Insider Activity
Insider Score Trend Over Time
-27.3 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
